Scroll for more

Japan

 

SPL (Sucampo Pharma, LLC)

 

Locations

 

Tokyo

1-1-7, Uchisaiwaicho, Chiyoda-ku
Tokyo 100-0011
Japan

Phone: +81-3-3596-8011
Fax: +81-3-3596-8023
Email: sucampopharmallc.info@sucampo.com


Sanda

4-1, Technopark, Sanda
Hyogo 669-1339
Japan

Phone: +81-79-560-7181
Fax: +81-79-560-7180
Email: sucampopharmallc.info@sucampo.com


Kobe

6-7-6, Minatojimaminamimachi, Chuo-ku, Kobe,
Hyogo 650-0047
Japan

Phone: +81-78-599-5340
Fax: +81-78-599-5352
Email: sucampopharmallc.info@sucampo.com

 

Description of SPL:

SPL works on the manufacture of AMITIZA and RESCULA
SPL manages the alliances with partners who sell RESCULA in Japan and Taiwan
SPL facilitates certain CMC, Pre-clinical and clinical activities, including lifecycle management for AMITIZA and research agreements with Japanese research universities

 

History of SPL:

  • In September 1989 R-Tech Ueno (RTU) was founded as a manufacturing, commercial and research and development pharmaceutical company.
  • In April 2001, RTU acquired the marketing and manufacturing operations for Rescula ® from Ueno Fine Chemicals Industry, Ltd.
  • In October 2004, the commercial rights for Rescula ® were transferred to Santen Pharmaceutical Co., Ltd. from Fujisawa Pharmaceutical Co, Ltd. In addition, RTU, Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Ltd. entered into a manufacturing and supply agreement for AMITIZA ®.
  • In September 2005, RTU obtained approval to manufacture AMITIZA ® from the U.S. Food and Drug Administration (FDA).
  • In April 2008, RTU became listed on the Tokyo Stock Exchange JASDAQ Standard (formerly Hercules, Osaka Securities Exchange).
  • In October 2008, RTU obtained approval to manufacture AMITIZA ® from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom.
  • In February 2009, RTU and Sucampo Pharma, Ltd. entered into an exclusive manufacturing and supply agreement for AMITIZA ® in Japan, Asia and Oceania.
  • In May 2010, RTU obtained approval to manufacture Rescula ® from the U.S. Food and Drug Administration (FDA).
  • In August 2015, Sucampo Pharmaceuticals, Inc. launched its tender offer to acquire RTU. As part of the transaction, RTU was delisted from the JASDAQ Stock Exchange in November. The acquisition was completed in December 2015.
  • On Oct.. 1, 2016, RTU was integrated into SPL.
 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.